The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
Open accessAbstract
Purpose: To develop recommendations about endocrine therapy for women with hormone receptor (HR) –positive metastatic breast cancer (MBC). Methods: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence. Outcomes of interest included sequencing of hormonal agents, hormonal agents compared with chemotherapy, targeted biologic therapy, and treatment of premenopausal women. This guideline puts forth recommendations for endocrine therapy as treatment for women with HR-positive MBC. Recommendations: Sequential hormone therapy is the preferential treatment for most women with HR-positive MBC. Except in cases of immediately life-threatening disease, hormone therapy, alone or in combination, should be used as initial treatment. Patients whose tumors express any level of hormone receptors should be offered hormone therapy. Treatment recommendations should be based on type of adjuvant treatment, disease-free interval, and organ function. Tumor markers should not be the sole criteria for determining tumor progression; use of additional biomarkers remains experimental. Assessment of menopausal status is critical; ovarian suppression or ablation should be included in premenopausal women. For postmenopausal women, aromatase inhibitors (AIs) are the preferred first-line endocrine therapy, with or without the cyclin-dependent kinase inhibitor palbociclib. As second-line therapy, fulvestrant should be administered at 500 mg with a loading schedule and may be administered with palbociclib. The mammalian target of rapamycin inhibitor everolimus may be administered with exemestane to postmenopausal women with MBC whose disease progresses while receiving nonsteroidal AIs. Among patients with HR-positive, human epidermal growth factor receptor 2–positive MBC, human epidermal growth factor receptor 2–targeted therapy plus an AI can be effective for those who are not chemotherapy candidates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Self-citationMouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jänicke, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2596 · Cited by 1,015
Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 992
Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
Bonneterre, J., Thürlimann, B., Robertson, J. F. R., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3748 · Cited by 842
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M., & Schiff, R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.117 · Cited by 704
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636
Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574
Self-citationHelping Patients Decide: Ten Steps to Better Risk Communication
Fagerlin, A., Zikmund-Fisher, B. J., & Ubel, P. A. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr318 · Cited by 573
Yardley, D. A., Noguchi, S., Pritchard, K. I., Burris, H. A., Baselga, J., Gnant, M., Hortobagyi, G. N., Campone, M., Pistilli, B., Piccart, M., et al. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0060-1 · Cited by 522
Self-citationChia, S., Gradishar, W., Mauriac, L., Bines, J., Amant, F., Federico, M., Fein, L., Romieu, G., Buzdar, A., Robertson, J. F. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5822 · Cited by 513
Cancer Patient Preferences for Communication of Prognosis in the Metastatic Setting
Hagerty, R. G., Butow, P. N., Ellis, P. A., Lobb, E. A., Pendlebury, S., Leighl, N., Goldstein, D., Lo, S. K., & Tattersall, M. H. N. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.095 · Cited by 503
Amir, E., Miller, N., Geddie, W., Freedman, O., Kassam, F., Simmons, C., Oldfield, M., Dranitsaris, G., Tomlinson, G., Laupacis, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5232 · Cited by 434 · cited 1×
“A number of studies have reported discordance between marker status in early- and late-stage disease, which results in a change in management in up to 14% of patients.(28) However, at present, there is a lack of clear evidence that a change in markers in the metastatic lesion is predictive of response to therapy.”
BackgroundKlijn, J. G. M., Blamey, R. W., Boccardo, F., Tominaga, T., Duchateau, L., & Sylvester, R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.343 · Cited by 425
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Van Poznak, C., Somerfield, M. R., Bast, R. C., Cristofanilli, M., Goetz, M. P., Gonzalez-Angulo, A. M., Hicks, D. G., Hill, E. G., Liu, M. C., Lucas, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1459 · Cited by 404
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., Gralow, J. R., Livingston, R. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201622 · Cited by 371
Self-citationGiordano, S. H., Temin, S., Kirshner, J. J., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Gonzalez-Angulo, A. M., Krop, I., Levinson, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0948 · Cited by 343
Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
Leo, A. D., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt337 · Cited by 321
Paridaens, R. J., Dirix, L. Y., Beex, L. V., Nooij, M., Cameron, D. A., Cufer, T., Piccart, M. J., Bogaerts, J., & Therasse, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4659 · Cited by 319
American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.04187.x · Cited by 308
Ellis, M. J., Gao, F., Dehdashti, F., Jeffe, D. B., Marcom, P. K., Carey, L. A., Dickler, M. N., Silverman, P., Fleming, G. F., Kommareddy, A., et al. (2009) · JAMA · doi:10.1001/jama.2009.1204 · Cited by 287
Self-citationJohnston, S. R., Kilburn, L. S., Ellis, P., Dodwell, D., Cameron, D., Hayward, L., Im, Y.-H., Braybrooke, J. P., Brunt, A. M., Cheung, K.-L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70322-x · Cited by 274
Self-citationWolff, A. C., Lazar, A. A., Bondarenko, I., Garin, A. M., Brincat, S., Chow, L., Sun, Y., Neskovic-Konstantinovic, Z., Guimaraes, R. C., Fumoleau, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3331 · Cited by 272
Bergh, J., Jönsson, P.-E., Lidbrink, E. K., Trudeau, M., Eiermann, W., Brattström, D., Lindemann, J. P. O., Wiklund, F., & Henriksson, R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.1095 · Cited by 263
Thompson, A. M., Jordan, L. B., Quinlan, P., Anderson, E., Skene, A., Dewar, J. A., Purdie, C. A., & the Breast Recurrence in Tissues Study Group (2010) · Breast Cancer Research · doi:10.1186/bcr2771 · Cited by 253
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Gibson, L., Lawrence, D., Dawson, C., & Bliss, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003370.pub3 · Cited by 252
Communicating prognosis to patients with metastatic disease: what do they really want to know?
Butow, P., Dowsett, S., Hagerty, R., & Tattersall, M. (2002) · Supportive Care in Cancer · doi:10.1007/s005200100290 · Cited by 251
Lobbezoo, D. J. A., van Kampen, R. J. W., Voogd, A. C., Dercksen, M. W., van den Berkmortel, F., Smilde, T. J., van de Wouw, A. J., Peters, F. P. J., van Riel, J. M. G. H., Peters, N. A. J. B., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2711-y · Cited by 248
Klijn, J. G. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.903 · Cited by 248
Partridge, A. H., Rumble, R. B., Carey, L. A., Come, S. E., Davidson, N. E., Di Leo, A., Gralow, J., Hortobagyi, G. N., Moy, B., Yee, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7479 · Cited by 240
Self-citationAge-Specific Incidence of Breast Cancer Subtypes: Understanding the Black–White Crossover
Clarke, C. A., Keegan, T. H. M., Yang, J., Press, D. J., Kurian, A. W., Patel, A. H., & Lacey, J. V. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs264 · Cited by 228
Huober, J., Fasching, P. A., Barsoum, M., Petruzelka, L., Wallwiener, D., Thomssen, C., Reimer, T., Paepke, S., Azim, H. A., Ragosch, V., et al. (2012) · The Breast · doi:10.1016/j.breast.2011.07.006 · Cited by 223
Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
Cheang, M. C. U., Martin, M., Nielsen, T. O., Prat, A., Voduc, D., Rodriguez-Lescure, A., Ruiz, A., Chia, S., Shepherd, L., Ruiz-Borrego, M., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0372 · Cited by 194
Schwartzberg, L. S., Franco, S. X., Florance, A., O'Rourke, L., Maltzman, J., & Johnston, S. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0240 · Cited by 188
Self-citationEstrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis
Pusztai, L., Viale, G., Kelly, C. M., & Hudis, C. A. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0059 · Cited by 182
Prat, A., & Baselga, J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1179 · Cited by 177
Amir, E., Clemons, M., Purdie, C. A., Miller, N., Quinlan, P., Geddie, W., Coleman, R. E., Freedman, O. C., Jordan, L. B., & Thompson, A. M. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.006 · Cited by 176
Ingle, J. N., Krook, J. E., Green, S. J., Kubista, T. P., Everson, L. K., Ahmann, D. L., Chang, M. N., Bisel, H. F., Windschitl, H. E., & Twito, D. I. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.2.178 · Cited by 173
Self-citationRobertson, J. F. R., Lindemann, J. P. O., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Emerson, L., Dean, A., & Ellis, M. J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2192-4 · Cited by 172
Original article: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
Howell, A., Dodwell, D. J., Anderson, H., & Redford, J. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058286 · Cited by 172
Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer
Wilcken, N., Hornbuckle, J., & Ghersi, D. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002747 · Cited by 165
Robertson, J. F., Ferrero, J.-M., Bourgeois, H., Kennecke, H., de Boer, R. H., Jacot, W., McGreivy, J., Suzuki, S., Zhu, M., McCaffery, I., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70026-3 · Cited by 165
Rugo, H. S., Pritchard, K. I., Gnant, M., Noguchi, S., Piccart, M. J., Hortobágyi, G. N., Baselga, J. M., Perez, A., Geberth, M., Csőszi, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu009 · Cited by 132
Self-citationMartín, M., Loibl, S., von Minckwitz, G., Morales, S. M., Martínez-Jáñez, N., Guerrero, Á., Antón, A., Aktas, B., Schoenegg, W., Muñoz-Mateu, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2388 · Cited by 131
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
André, F., & Cortés, J. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3301-y · Cited by 113
Racial and Ethnic Disparities in Care: The Perspectives of Cardiologists
Lurie, N., Fremont, A., Jain, A. K., Taylor, S. L., McLaughlin, R., Peterson, E., Kong, B. W., & Ferguson, T. B. (2005) · Circulation · doi:10.1161/01.cir.0000157738.12783.71 · Cited by 109
Yamashita, H., Ando, Y., Nishio, M., et al. (2006) · Breast Cancer · doi:10.2325/jbcs.13.74 · Cited by 105
Tobin, N. P., Harrell, J. C., Lövrot, J., Brage, S., Stolt, M. F., Carlsson, L. M. S., Einbeigi, Z., Linderholm, B. K., Loman, N., Malmberg, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu498 · Cited by 99
Johnston, S. R. D. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv212 · Cited by 92
Self-citationBurstein, H. J., Cirrincione, C., Barry, W. T., Chew, H. K., Tolaney, S. M., Lake, D. E., Ma, C. X., Blackwell, K., Winer, E. P., & Hudis, C. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7941 · Cited by 89
Self-citationBaselga, J. M., Im, S., Iwata, H., Clemons, M. J., Ito, Y., Awada, A. H., Chia, S., Jagiełło-Gruszfeld, A., Pistilli, B., Tseng, L.-M., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s6-01 · Cited by 89
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
Hernandez-Aya, L. F., & Ma, C. X. (2016) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2016.09.017 · Cited by 89
Carlson, R. W., Theriault, R. L., Schurman, C. M., Rivera, E., Chung, C. T., Phan, S.-C., Arun, B., Dice, K., Chiv, V., Green, M. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9565 · Cited by 88
Vidula, N., & Rugo, H. S. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.07.005 · Cited by 87
Self-citationAapro, M., André, F., Blackwell, K., Calvo, E., Jahanzeb, M., Papazisis, K. T., Porta, C., Pritchard, K. I., & Ravaud, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu021 · Cited by 76
Self-citationSuman, V. J., Ellis, M. J., & Ma, C. X. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.09.01 · Cited by 67
on behalf of the Austrian Breast and Colorectal Cancer Study Group, Gnant, M., Pfeiler, G., Stöger, H., Mlineritsch, B., Fitzal, F., Balić, M., Kwasny, W., Seifert, M., Stierer, M., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.367 · Cited by 60
Reisenbichler, E., Lester, S. C., Richardson, A. L., et al. (2013) · American Journal of Clinical Pathology · doi:10.1309/ajcp1rf9fuizrdpi · Cited by 56
Iwata, H., Masuda, N., Ohno, S., Rai, Y., Sato, Y., Ohsumi, S., Hashigaki, S., Nishizawa, Y., Hiraoka, M., Morimoto, T., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2573-3 · Cited by 54
Abrams, J. S., Aisner, J., Cirrincione, C., Berry, D. A., Muss, H. B., Cooper, M. R., Henderson, I. C., Panasci, L., Kirshner, J., Ellerton, J. A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.64 · Cited by 49
Self-citationJohnston, S. R. D., Basik, M., Hegg, R., Lausoontornsiri, W., Grzeda, L., Clemons, M. J., Dreosti, L., Mann, H., Stuart, M., & Cristofanilli, M. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3979-5 · Cited by 46
Self-citationCope, S. F., Ouwens, M., Jansen, J. P., & Schmid, P. (2013) · Value in Health · doi:10.1016/j.jval.2012.10.019 · Cited by 40
Lux, M. P., Bayer, C. M., Loehberg, C. R., Fasching, P. A., Schrauder, M. G., Bani, M. R., Häberle, L., Engel, A., Heusinger, K., Tänzer, T. D., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2557-3 · Cited by 36
Obesity, insulin resistance and breast cancer outcomes
Goodwin, P. J. (2015) · The Breast · doi:10.1016/j.breast.2015.07.014 · Cited by 31
Rugo, H. S. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.09.004 · Cited by 27
Self-citationXu, B., Jiang, Z., Shao, Z., Wang, J., Feng, J., Song, S., Chen, Z., Gu, K., Yu, S., Zhang, Y., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1483-x · Cited by 26
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
Russell, C. A. (2013) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2013.07.033 · Cited by 22
Ma, C. X., & Ellis, M. J. (2009) · Breast Diseases A Year Book Quarterly · doi:10.1016/s1043-321x(09)79368-3 · Cited by 22
Effects of toremifene versus tamoxifen on breast cancer patients: a meta-analysis
Chi, F., Wu, R., Zeng, Y., Xing, R., Liu, Y., & Xu, Z. (2012) · Breast Cancer · doi:10.1007/s12282-012-0430-6 · Cited by 19
Johnston, S. R. D., Basik, M., Hegg, R., Lausoontornsiri, W., Grzeda, L., Clemons, M. J., Dreosti, L., Ghiorghiu, S., Mann, H., Landers, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.531 · Cited by 19
Self-citationRobertson, J. F. R., Llombart‐Cussac, A., Feltl, D., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-s6-04 · Cited by 18
Tan, P. S., Haaland, B. A., Montero, A. J., & Lopes, G. D. L., Jr. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2495-0 · Cited by 18
Tan, P. S., Haaland, B. A., Montero, A. J., & Lopes, G. D. L., Jr. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.e11591 · Cited by 2
Cited by
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Metadata
- Authors
- Rugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L., Fowble, B., Ingle, J. N., Jahanzeb, M., Johnston, S. R. D., Korde, L. A., Khatcheressian, J. L., Mehta, R. S., Muss, H. B., & Burstein, H. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-09-01
- Volume
- 34
- Issue
- 25
- Pages
- 3069-3103
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2404884142
- Cited by
- 633
- References
- 82
- FWCI
- 58.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.